Drug intelligence / Profile preview

Clagen

Development stage
Unknown
Lead developer
Cadila Pharmaceuticals
Modality
Recombinant Proteins and Enzymes, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Clagen is a multi-ingredient nutraceutical combination therapy indicated for the management of pain and inflammation in patients with osteoarthritis (OA), particularly of the knee. The formulation consists of four key components: Aflapin (a standardized *Boswellia serrata* extract), native type 2 collagen, Mobilee (a proprietary hyaluronic acid matrix containing polysaccharides and collagen), and CurQlife (a bioavailable curcumin extract). Clagen works through a synergistic mechanism involving the inhibition of pro-inflammatory enzymes such as 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2), as well as providing structural support to joint cartilage and synovial fluid. Clinical studies have demonstrated its efficacy in reducing Visual Analog Scale (VAS) pain scores and improving joint function and quality of life, positioning it as a potential long-term alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs) to mitigate risks of gastrointestinal and renal toxicity.

Brand names
Clagen
02

Targets

ALOX5 (Arachidonate 5-lipoxygenase)NF-κBPTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Clagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clagen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call